Rexahn Pharmaceuticals, Inc. (REXN)

[conix]

1. Rexahn Pharmaceuticals: Up 370%

Rexahn Pharmaceuticals Inc. (NYSEMKT: RNN) has been a screamer in 2017, up well over 300% year to date. At $0.67 a share, its market cap is close to $155 million. While the stock was at $0.62 at the time, the analyst at Rodman & Renshaw assigned a new Buy rating and $2 price target on April 6. Rexahn has clinical stage drug candidates targeting pancreatic cancer, bladder cancer, breast cancer, kidney cancer and other tumors.

Rexahn’s 52-week trading range is $0.13 to $0.71, but it has a long history of price volatility, as well as a price under $5 back to 2006.